We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Avacta | AVCT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 1.00 | 2.13% | 48.00 | 14:47:17 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 47.00 | 47.00 | 49.50 | 48.00 | 47.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 20/11/2024 08:24 by m_night10 POLX Polarean Imaging 1.6p I fancy to fill the gap to 3.2p and head to 10p+. Mcap is peanuts 1/10th of AVCT and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil in 2025 Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars as used to trade at 100p and has made significant commercial progress since FDA approval. Massive takeover target and will be sold for 20p+ share price. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice. |
Posted at 24/10/2024 09:19 by lomcovaks 1347,You'll have to do better fear mongering than that. When #AVCT first published their 2nd asset AVA3996, a proteosome inhibitor, they announced the estimated market of which was $2.3 Billion dollars by 2026. Press release dated 18th Jan 2022. On the other hand, the estimated market for Antibody Drug Conjugates in 2026 is over $21 Billion dollars with annual compound growth of 29.57% Today's RNS suggests that Avacta's Pre|cision delivery method is FAR superior to any ADC in the market currently or likely in the future. . The board have clearly targeted the correct market. Rather than other candidates 'falling by the wayside', the company is clearly confident that the safety data they have has permitted them to utilize a much more toxic warhead. I first bought in 2019 and have accumulated ever since. I understand it's super high risk but I don't need unthoughtful comments like yours that don't carry any weight when tested against reality. |
Posted at 23/10/2024 16:40 by idle jack I've been in Tempus AI since just after ipo and have dabbled in avct back in the Covid days. Tem deal has the potential to unlock huge access to data concerning what avct are trying to develop. Not so sure it's the AI flavour of the month element at the moment which will no doubt develop, more the database, that would be cumbersome for anyone else to develop. But the AI will certainly come to fruition. Top owner that founded groupon and huge institutional investor support (inc Google). Good move that and I hope it accelerates avct as they are doing good work. |
Posted at 22/10/2024 13:58 by rajraj b You do realise they took multiple biopsy samples through the trials ( 2 week and 3 week) all showing active Dox in the biopsies and in large concentrations. Plus they have scans showing shrinking tumour masses for patients on the trial, who were given no hope. You really should read their decks on the AVCT website. That way you might be more up to date in your thinking and less confused about all this. |
Posted at 21/10/2024 15:13 by 1347 As I and others have pointed out, recent powder puff RNS announcements were merely desiged to help forward sell the next pay day loan/death spiral finance conversion. Still £30 m to go and ever and ever lower prices. Heading for 10p?London - Oct. 21, 2024 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces it has issued and allotted a total of 5,930,659 new ordinary shares of 10 pence each in the Company ("New Ordinary Shares"). The New Ordinary Shares are being issued in settlement of the quarterly principal of £2.55 million and interest repayment of £0.54 million in respect of the Company's unsecured convertible bond. After settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by £2.55 million to £30.60 million. |
Posted at 17/10/2024 07:52 by 1347 So again what happened to AVA3996, or are they now tacitly admitting that AVA6000 was such a failure (as their Affimer based tests were) that they are not proceeding with the two candidates they got from Arisaph?"18 January 2022 Avacta Selects Second pre|CISIONTM Pro-drug Candidate for Development Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISIONTM drug candidate, AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning in the second half of 2023." What happened with their last pre-clinical pipeline candidates, AVA-021, AVA-028, AVA-032? Seems they were all quietly dropped, hoping no-one would notice? Well some of us have. Looks to me as if they just want to find some new pre-clinical candidates so they can kick off another 3 year Phase trial, have more placings to ‘advance’ I notice the announcements come just before the next payday loan payment is due, which I doubt will be paid by cash this time. I reckon ‘investorsR |
Posted at 10/10/2024 08:13 by 1347 This looks to me like typical Avacta, they have to find new rainbows to cover up for the fact that the old ones disappeared like scotch mist on a sunny day. As well as the longest running Phase 1 trial I've ever known, what the hell happened to their second candidate AVA3996, it was supposed to be in Phase 1 a year ago?18 January 2022 "Avacta Selects Second pre|CISIONTM Pro-drug Candidate for Development Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISIONTM drug candidate, AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning in the second half of 2023." |
Posted at 10/10/2024 06:30 by robers98 Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments, today announced that the Company will present new preclinical data on two breakthroughs in the pre|CISION™ platform in poster sessions at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain from 23-25 October 2024. Together, the presentations advance the utility of our pre|CISION™ drug delivery platform technology, which delivers highly potent warheads directly to the tumor microenvironment while minimizing exposure in normal tissues, thus allowing dosing to be optimized to deliver the best outcomes for patients.The first advance in the pre|CISION™ platform is the design and preclinical analysis of the Company’s newest development candidate, AVA6103, a novel, potent peptide drug conjugate (PDC) that FAP-enables the most potent Topoisomerase I inhibitor in clinical testing, via the pre|CISION™ technology with tumor-specific delivery of the warhead to induce DNA damage and drive cancer cell death. AVA6103 is a Generation Two pre|CISION™ PDC in the Avacta pipeline. The second advance in the pre|CISION™ platform is the first description of a novel class of engineered biotherapeutics, called Affirmer® Drug Conjugates, that are dual-targeting and have the potential to offer a delivery mechanism with greater specificity than the PDC, thus potentially unlocking the patient populations with low expression of FAP in the tumor. This program is a Generation Three pre|CISION™ medicine and utilizes the same release mechanism in the pre|CISION™ platform. Based on this, the Affimer drug conjugates have the potential to not only increase the specificity of delivery but to also minimize systemic exposure to the warhead. |
Posted at 10/9/2024 12:22 by stmcn Hi Divmad - no justification for PW71’s libellous comment but the (highly extended/indetermina |
Posted at 03/6/2024 09:25 by pwhite73 Rajraj b - Yes I still do. AVCT has just raised £28 million. It is my opinion they are not going to waste anymore money on the never ending AVA6000 Phase 1 trials. AVCT needs to boost the share price or they can't meet their loan obligations without totally destroying what's left of shareholder value.AVCT and SOFIE are both looking at the use of FAP to kill cancer cells. AVCT as a means of recognition and SOFIE as a means of inhibition. RNS 28/03/24 - "This sub-study represents an ongoing collaboration between Avacta and SOFIE, in the use of [18F]FAPI-74 PET as a complementary diagnostic. [18F]FAPI-74 PET is currently in clinical development and for investigational use only." So we know they have been working together prior to the date of the RNS. A full joint venture to kill cancer cells will perhaps give AVCT the boost they so desperately need. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
